Aflibercept is a vascular endothelial growth factor (VEGF) inhibitor used to treat Neovascular (Wet) Age-Related Macular Degeneration (AMD), various types of macular edema and diabetic retinopathy, and metastatic colorectal cancer. Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors, VEGFR1 and VEGFR2, fused with the Fc region of human immunoglobulin gamma 1 (IgG1).
- Mechanism
- Curator reviewed · 2 references
Ablibercept is a recombinant fusion protein that acts as a decoy receptor for the ligands, vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PIGF). It prevents these ligands to binding to endothelial receptors, VEGFR-1 and VEGFR-2, to suppress neovascularization and decrease vascular permeability. This ultimately will slow vision loss or the progression of metastatic colorectal cancer.
- Primary indication
- The opthalmic agent is used for the treatment of neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR), and retinopathy of prematurity (ROP).Curator reviewed · 12 structured indications
- Formula / weight
- C4318H6788N1164O1304S32 · 115000.0 Da (with glycosylation, constituting an additional 15% of the total molecular mass)
- First approval
- Canada, 2013 · United States, 2011 · European Union, 2016
- Also known as
- Aflibercept (genetical recombination) · aflibercept-abzv · aflibercept-jbvf · aflibercept-mrbb · aflibercept-yszy
- Code names
- AVE-0005 · AVE 005 · BAY-865321 · SCD411
- Brand names
Resolves to
What you can answer from here — as of May 26, 2026
Which drugs share a target with Aflibercept, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account